The Diabetes Medication Satisfaction Tool (DMSAT): A Focus on Treatment Regimens
- Roger T. Anderson, PhD (rtanders{at}psu.edu)(1),
- Cynthia J. Girman(2),
- Manjiri D. Pawaskar, PhD(3),
- Fabian T. Camacho(4),
- Jorge Calles, MD(5),
- William S. Kelly, MD(6),
- Carla DeMuro(7) and
- Rajesh Balkrishnan, PhD(3)
- 1. Penn State University, College of Medicine, Hershey, PA
- 2. Merck Research Laboratories, Epidemiology Department, West Point, PA
- 3. Department of Pharmacy Practice and Administration, Ohio State University College of Pharmacy, Columbus, OH
- 4. Penn State University, College of Medicine, A210 Public Health Sciences, Hershey, PA
- 5. Wake Forest University School of Medicine, Winston-Salem, NC
- 6. Kernersville Primary Care, Kernersville, NC
- 7. RTI Health Solutions, Patient Reported Outcomes, Research Triangle Park, NC
Abstract
Research: Treatment complexity, side effects, and multiple medications are important in assessing diabetes treatment satisfaction.
Design and Methods: Survey items were developed from community clinic focus groups, pre-tested in patients with diabetes, and examined in two samples of treated patients.
Results: 16 items performed well in assessing treatment experiences: ease and convenience, lifestyle burdens, well-being, and medical control. Construct validity was supported by associations (p<0.05) with treatment complexity, self-rated glucose control, health worries, and HbA1c. Internal consistency ranged from .89 - .95.
Conclusion: The DMSAT offers a comprehensive assessment of patient acceptability with diabetes therapy useful to individualize therapeutic decision making.
Footnotes
-
- Received July 3, 2008.
- Accepted September 26, 2008.
- Copyright © American Diabetes Association
